Press release – For immediate release – 5:45 pm CET
Median Technologies meets the eligibility conditions for the PEA-PME scheme
Median Technologies (FR0011049824, ALMDT) confirms its eligibility for the PEA-PME scheme in accordance with the provisions of Articles L. 221-32-2 and D. 221-113-5 and following of the Monetary and Financial Code specifying the conditions for assessing the eligibility criteria, i.e.:
- Less than 5,000 employees,
- An annual turnover of less than 1.5 billion euros or a balance sheet total of less than 2 billion euros.
Median Technologies shares therefore continue to be included in PEA-PME accounts, which for the record benefit from the same tax advantages as the traditional stock savings plan (PEA).
Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median’s offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China is listed on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).